Barings’s Neurocrine Biosciences NBIX Stock Holding History

Barings’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-25,190	Closed	-$3.1M	–	735
2018 Q3	$3.1M	Buy	+25,190	New	+$2.86M	0.04%	258

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Barings's NBIX Position: Q4 2018 in Review

Barings sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 25,190 shares — an estimated $3.1M sold.

Barings first reported a position in NBIX in Q3 2018 and held it in 1 quarter. The position peaked at $3.1M in Q3 2018. 330 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

Barings reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
Barings sold 25,190 Neurocrine Biosciences shares in Q4 2018, an estimated $3.1M.
Barings first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 1 quarter.
Barings's Neurocrine Biosciences position peaked at $3.1M in Q3 2018.
330 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Barings's 13F filing for Q4 2018, filed 7 Feb 2019.